Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

June 3, 2022

Study Completion Date

August 24, 2022

Conditions
GlioblastomaMGMT-Unmethylated Glioblastoma
Interventions
DRUG

Microtubule-Targeted Agent BAL101553

Given PO

RADIATION

Radiation Therapy

Undergo radiation therapy

Trial Locations (8)

15232

Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh

19104

Abrams Cancer Center of the University of Pennsylvania, Philadelphia

21205

Johns Hopkins University, Baltimore

27157

Wake Forest University Comprehensive Cancer Center, Winston-Salem

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

48202

Henry Ford Hospital, Detroit

35294-3410

UAB Comprehensive Cancer Center, Birmingham

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

lead

Basilea Pharmaceutica

INDUSTRY